Brief: Longeveron® Announces Nature Medicine Publication Of Results Of Phase 2A Clinical Trial Evaluating Laromestrocel (Lomecel-B™) In Alzheimer’S Disease
11/03/2025 14:17
March 11 (Reuters) - Longeveron Inc LGVN.O: LONGEVERON® ANNOUNCES NATURE MEDICINE PUBLICATION OF RESULTS OF PHASE 2A CLINICAL TRIAL EVALUATING LAROMESTROCEL (LOMECEL-B™) IN ALZHEIMER’S DISEASE LONGEVERON INC - LAROMESTROCEL FIRST CELLULAR THERAPY TO RECEIVE FDA RMAT DESIGNATION FOR ALZHEIMER'S LONGEVERON INC - TRIAL ACHIEVED PRIMARY SAFETY AND SECONDARY EFFICACY ENDPOINTS Source text: ID:nGNXc4Vl48 Further company coverage: LGVN.O ((Reuters.Briefs@thomsonreuters.com;))